The purpose of this study is to establish a safe dose of study cells (ATLCAR.CD30.CCR4 and ATLCAR.CD30) to give to patients with CD30+ refractory/relapsed Hodgkin's Lymphoma and Cutaneous T-Cell Lymphoma.

Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.

Have you been diagnosed with melanoma? If so, you may be eligible to take part in a research study looking at the safety of giving a combination of drugs called Ulixertinib and Palbociclib to patients with advanced melanoma.

The purpose of this study is to establish a safe dose of study cells (ALTCAR.CD30) to give after chemotherapy and estimate progression free survival in pediatric patients with CD30+ refractory/relapsed Hodgkin lymphoma (HL) and non-Hodgkin lymphoma.

Do you have bladder, kidney, prostate, or another genitourinary cancer diagnosis? If so, you may be able to take part in a research study collecting specimens (e.g., blood, urine, saliva, tissue) during your already scheduled appointments. Collecting these specimens may help researchers develop new ways to detect cancer earlier or to more effectively treat cancer.

Better understand symptoms that occur after liver-directed treatments for liver cancer

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.

We will collect one more round of data from participants >= 45 years and analyze factors associated with aging and cognitive function.

To find out if the addition of 2 blocks of inotuzumab ozogamicin to the standard chemotherapy regimen will improve outcomes in children and young adults with High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).

The primary objective of this repository is to make blood samples available for research studies related to histocompatibility and HC transplantation or other cellular therapy.